Sharekhan

Windlas Biotech Ltd

Mon 7/07/2025,15:58:50 | NSE : WINDLAS

₹ 906.553.30 (0.37%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 903.30

Previous Close

₹ 903.25

Volume

23498

Mkt Cap ( Rs. Cr)

₹1900.07

High

₹ 910.25

Low

₹ 890.40

52 Week High

₹ 1198.25

52 Week Low

₹ 659.00

Book Value Per Share

₹ 224.83

Dividend Yield

0.00

Face Value

₹ 5.00

What’s Your Call?

Collective community sentiment on Windlas Biotech Ltd

Your Vote -

Buy

21.74%

Hold

56.52%

Sell

21.74%

21.74%

46 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

NaN%

Sell Order Quantity

NaN%

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Option Chain

Analyzes market sentiment, predicts Windlas Biotech Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Windlas Biotech - General Updates

    4 Jul 2025, 12:40PM Windlas Biotech Limited has informed the Exchange about General Updates on Newspaper Publication
  • Windlas Biotech - Analysts/Institutional Investor Meet/Con. Call Updates

    30 Jun 2025, 11:17AM Windlas Biotech Limited has informed the Exchange about Schedule of meet
  • Windlas Biotech - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    30 Jun 2025, 11:13AM Intimation of Schedule of Analyst / Institutional Investor meetings under the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015
  • Windlas Biotech - Trading Window-XBRL

    27 Jun 2025, 6:00PM WINDLAS BIOTECH LIMITED has informed the Exchange about Closure of Trading Window
  • Windlas Biotech - Trading Window

    27 Jun 2025, 5:58PM Windlas Biotech Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations,
  • Windlas Biotech - Analysts/Institutional Investor Meet/Con. Call Updates

    13 Jun 2025, 3:09PM Windlas Biotech Limited has informed the Exchange about Schedule of meet
  • Windlas Biotech - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    13 Jun 2025, 3:04PM Intimation of Schedule of Analyst / Institutional Investor meetings under the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 201
  • Windlas Biotech - Analysts/Institutional Investor Meet/Con. Call Updates

    29 May 2025, 3:12PM Windlas Biotech Limited has informed the Exchange about Transcript
  • Windlas Biotech - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

    29 May 2025, 3:07PM Earning Call Transcript for Q4 of FY25 enclosed.
  • Windlas Biotech - Analysts/Institutional Investor Meet/Con. Call Updates

    26 May 2025, 6:05PM Windlas Biotech Limited has informed the Exchange about Schedule of meet
  • Windlas Biotech - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    26 May 2025, 6:01PM Intimation of Schedule of Analyst / Institutional Investor meetings under the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 201
  • Windlas Biotech - Analysts/Institutional Investor Meet/Con. Call Updates

    23 May 2025, 4:13PM Windlas Biotech Limited has informed the Exchange about Link of Recording
  • Windlas Biotech - Recording Of Conferencing Call

    23 May 2025, 4:09PM Recording of conference call
  • Windlas Biotech - Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent

    22 May 2025, 6:52PM WINDLAS BIOTECH LIMITED has informed the Exchange about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Age
  • Windlas Biotech - Outcome of Board Meeting-XBRL

    22 May 2025, 6:48PM WINDLAS BIOTECH LIMITED has informed the Exchange regarding Outcome of Board Meeting held on 22-May-2025 for Dividend
  • Windlas Biotech - Change in Auditors

    22 May 2025, 6:26PM Windlas Biotech Limited has informed the Exchange regarding Change in Auditors of the company.
  • Windlas Biotech - Announcement under Regulation 30 (LODR)-Change in Management

    22 May 2025, 6:17PM Appointment of statutory auditors and secretarial auditors subject to approval of shareholders.
  • Windlas Biotech - Outcome of Board Meeting

    22 May 2025, 6:01PM Windlas Biotech Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.
  • Windlas Biotech - Press Release

    22 May 2025, 5:21PM Windlas Biotech Limited has informed the Exchange regarding a press release dated May 22, 2025, titled ""Windlas Biotech Limited Reports its Q4 and FY
  • Windlas Biotech - Investor Presentation

    22 May 2025, 5:17PM Windlas Biotech Limited has informed the Exchange about Investor Presentation
  • Windlas Biotech - Outcome of Board Meeting

    22 May 2025, 5:13PM Windlas Biotech Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.
  • Windlas Biotech - Board Meeting Outcome for Approval Of Financial Results For The Quarter And Financial Year Ended March 31,

    22 May 2025, 5:56PM Approval of financial results for the quarter and financial year ended March 31, 2025 (Revised Announcement with Annexure 2)
  • Windlas Biotech - Results For The Quarter And Financial Year Ended March 31, 2025

    22 May 2025, 5:40PM Results for the quarter and financial year ended March 31, 2025
  • Windlas Biotech - Announcement under Regulation 30 (LODR)-Investor Presentation

    22 May 2025, 5:31PM Results Presentation for the quarter and financial year ended March 31, 2025.
  • Windlas Biotech - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    22 May 2025, 5:27PM Windlas Biotech Limited reports its Q4 and FY25 financial results.
  • Windlas Biotech Q4 net profit down 3.89% at Rs 16.29 cr

    22 May 2025, 5:02PM The company reported standalone net profit of Rs 16.29 crore for the quarter ended March 31, 2025 as compared to Rs 16.95 crore in the same period las
  • Windlas Biotech - Board Meeting Outcome for Outcome Of The Board Meeting

    22 May 2025, 4:58PM Outcome of the Board Meeting for consideration of financial results and recommendation of dividend
  • Windlas Biotech - Analysts/Institutional Investor Meet/Con. Call Updates

    14 May 2025, 2:19PM Windlas Biotech Limited has informed the Exchange about Schedule of meet
  • Windlas Biotech - Board Meeting Intimation

    14 May 2025, 2:01PM WINDLAS BIOTECH LIMITED has informed the Exchange about Board Meeting to be held on 22-May-2025 to consider and approve the Yearly Audited Financial r
  • Windlas Biotech - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    14 May 2025, 1:08PM Schedule of Conference Call to discuss financial performance for quarter and financial year ended March 31, 2025.
  • Windlas Biotech - Board Meeting Intimation for Notice Of The Board Meeting Scheduled To Be Held On Thursday, May 22, 2025

    14 May 2025, 1:02PM Windlas Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/05/2025 ,inter alia, to consider and
  • Windlas Biotech - Analysts/Institutional Investor Meet/Con. Call Updates

    17 Apr 2025, 3:08PM Windlas Biotech Limited has informed the Exchange about Schedule of meet
  • Windlas Biotech - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    17 Apr 2025, 3:03PM Intimation of Schedule of Analyst / Institutional Investor meetings under the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 201
  • Windlas Biotech has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2025

    16 Apr 2025, 4:21PM As of March 2025, 62.34% is owned by Indian Promoters and 37.66% by Public. <p align=justify> Top three Promoters holding highest number of shares of
  • Windlas Biotech - Certificate under SEBI (Depositories and Participants) Regulations, 2018

    8 Apr 2025, 5:22PM Windlas Biotech Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
  • Windlas Biotech - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    8 Apr 2025, 5:17PM Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulation, 2018 for the quarter ended 31st March, 2025
  • Windlas Biotech - Credit Rating

    8 Apr 2025, 1:55PM Windlas Biotech Limited has informed the Exchange about Credit Rating
  • Windlas Biotech - Announcement under Regulation 30 (LODR)-Credit Rating

    8 Apr 2025, 1:46PM Reaffirmation of Credit Rating by ICRA Limited
  • Windlas Biotech

    2 Feb 2022 , 9:47AM Windlass Biotech: The company’s plant IV at Dehradhun underwent an inspection from the SAPHRA (South African Health Products Regulatory Authority) between 20-29th September 2021. The inspection ended with zero critical observations/ deficiencies, zero major deficiencies and some minor deficiencies. This is positive as a successful inspection would open up new geography and help it strengthen its presence in South Africa.

Key fundamentals

Evaluate the intrinsic value of Windlas Biotech Ltd stock 

Name March-25 March-24 March-23 March-22 March-21
Assets 532.905 450.4 403.109 401.247 229.227
Liabilities 532.905 450.4 403.109 401.247 229.227
Equity 10.48 10.399 10.463 10.897 6.411
Gross Profit 94.115 78.102 60.242 52.895 54.692
Net Profit 60.649 58.144 42.644 38.561 5.01
Cash From Operating Activities 68.232 108.911 60.982 8.997 11.448
NPM(%) 7.98 9.21 8.31 8.27 1.17
Revenue 759.878 630.956 513.083 465.93 427.602
Expenses 665.763 552.854 452.841 413.035 372.91
ROE(%) 12.87 12.33 9.04 8.18 1.06

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day
5.8 116 0 970.95
17 Sep 2024 5.5 110 0 607.95
09 Sep 2022 3.5 70 0 215.8

Peers

Other companies within the same industry or sector that are comparable to Windlas Biotech Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 923.60 -2.42 30.64 513.93 301.39 0.54
Lotus Eye Hospital and Institute Ltd 75.35 4.84 215.29 1872.71 3.55 0.00
Vaishali Pharma Ltd 11.81 3.32 196.83 965.26 3.13 0.00
Astec Lifesciences Ltd 933.35 -1.23 0.00 1765.80 -601.21 0.00

Company Info

The Company was incorporated as `Windlas Biotech Limited' on February 19, 2001 at New Delhi as a public limited company under the Companies Act, 1956 and was granted a certificate of incorporation by RoC Delhi. Further, the Company received the certificate for commencement of business on March 5, 2001 from the RoC Delhi. The Registered Office of the Company was shifted from the state of Delhi to the state of Uttarakhand pursuant to a special resolution passed by the Shareholders on August 22, 2009. The alteration with respect to the place of the Registered Office was confirmed by the order of the Company Law Board, New Delhi on August 5, 2010 and a fresh certificate of registration was issued by the Registrar of Companies, Uttar Pradesh and Uttarakhand located at Kanpur on February 18, 2011. Subsequently, the Company was converted into a private limited company pursuant to a special resolution passed by the Shareholders on March 30, 2016 and a fresh certificate of incorporation consequent upon conversion and change of name to `Windlas Biotech Private Limited' was granted by the Registrar of Companies, Uttarakhand located at Kanpur on July 22, 2016. the Company was converted from a private limited company to a public limited company pursuant to a special resolution passed by the Shareholders on April 3, 2021, and the name of the Company was changed to `Windlas Biotech Limited'. A fresh certificate of incorporation dated April 15, 2021 consequent upon change of name on conversion to a public limited company was granted by the RoC.Major events and milestones of the Company :2001- Commenced operations at Dehradun Plant - I situated at 40/1, Mohabewala Industrial Area, Dehradun 248 110 and initiated commercial production2009- Commenced operations at Dehradun Plant - IV situated at plot no. 183 and 192, Mohabewala Industrial Area, Dehradun 248 1102010- Revenues crossed Rs. 1,000 million for the FY 2009-102014- Received first USFDA inspection clearance for the WHC Plant- Revenues crossed Rs. 2,000 million for the FY 2013-14- Commenced operations at Dehradun Plant - II situated at khasra no. 141 to 143 and 145, Mohabewala Industrial Area, Dehradun 248 1102015- Investment of Rs. 750 million from Tano India Private Equity Fund II2017- Revenues crossed Rs. 3,000 million for the FY 2016-172018- Launched first product in the United States from the Dehradun Plant - IV situated at plot no. 183 and 192, Mohabewala Industrial Area, Dehradun 248 110- Commenced operations at Dehradun Plant - III situated at plot no. 39, Pharmacity, Selaqui, Dehradun 248 1972021- Approval of Scheme of Amalgamation of the erstwhile subsidiary, Windlas Healthcare, with and into the Company 2022 -Company received certificate of Good Manufacturing Practices (GMP) from SAHPRA (South African Health Products Regulatory Authority).

The Company was incorporated as `Windlas Biotech Limited' on February 19, 2001 at New Delhi as a public limited company under the Companies Act, 1956 and was granted a certificate of incorporation by RoC Delhi. Further, the Company received the certificate for commencement of business on March 5, 2001 from the RoC Delhi. The Registered Office of the Company was shifted from the state of Delhi to the state of Uttarakhand pursuant to a special resolution passed by the Shareholders on August 22, 2009. The alteration with respect to the place of the Registered Office was confirmed by the order of the Company Law Board, New Delhi on August 5, 2010 and a fresh certificate of registration was issued by the Registrar of Companies, Uttar Pradesh and Uttarakhand located at Kanpur on February 18, 2011. Subsequently, the Company was converted into a private limited company pursuant to a special resolution passed by the Shareholders on March 30, 2016 and a fresh certificate of incorporation consequent upon conversion and change of name to `Windlas Biotech Private Limited' was granted by the Registrar of Companies, Uttarakhand located at Kanpur on July 22, 2016. the Company was converted from a private limited company to a public limited company pursuant to a special resolution passed by the Shareholders on April 3, 2021, and the name of the Company was changed to `Windlas Biotech Limited'. A fresh certificate of incorporation dated April 15, 2021 consequent upon change of name on conversion to a public limited company was granted by the RoC.Major events and milestones of the Company :2001- Commenced operations at Dehradun Plant - I situated at 40/1, Mohabewala Industrial Area, Dehradun 248 110 and initiated commercial production2009- Commenced operations at Dehradun Plant - IV situated at plot no. 183 and 192, Mohabewala Industrial Area, Dehradun 248 1102010- Revenues crossed Rs. 1,000 million for the FY 2009-102014- Received first USFDA inspection clearance for the WHC Plant- Revenues crossed Rs. 2,000 million for the FY 2013-14- Commenced operations at Dehradun Plant - II situated at khasra no. 141 to 143 and 145, Mohabewala Industrial Area, Dehradun 248 1102015- Investment of Rs. 750 million from Tano India Private Equity Fund II2017- Revenues crossed Rs. 3,000 million for the FY 2016-172018- Launched first product in the United States from the Dehradun Plant - IV situated at plot no. 183 and 192, Mohabewala Industrial Area, Dehradun 248 110- Commenced operations at Dehradun Plant - III situated at plot no. 39, Pharmacity, Selaqui, Dehradun 248 1972021- Approval of Scheme of Amalgamation of the erstwhile subsidiary, Windlas Healthcare, with and into the Company 2022 -Company received certificate of Good Manufacturing Practices (GMP) from SAHPRA (South African Health Products Regulatory Authority).

Read More

Parent Organisation

Windlas Biotech Ltd.

Founded

19/02/2001

Managing Director

Mr.Hitesh Windlass

NSE Symbol

WINDLASEQ

FAQ

The current price of Windlas Biotech Ltd is ₹ 906.55.

The 52-week high for Windlas Biotech Ltd is ₹ 910.25 and the 52-week low is ₹ 890.40.

The market capitalization of Windlas Biotech Ltd is currently ₹ 1900.07. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Windlas Biotech Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Windlas Biotech Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Windlas Biotech Ltd shares.

The CEO of Windlas Biotech Ltd is Mr.Hitesh Windlass, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT